Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 31562 | 151 | 33.3 | 76% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
| 442 | 3 | DERMATOLOGY//VITILIGO//DERMATOL | 26460 |
| 3766 | 2 | MINOCYCLINE//BLACK THYROID//COL 3 | 1000 |
| 31562 | 1 | COL 3//CHEMICALLY MODIFIED TETRACYCLINES//MANCHESTER CELLULAR METAB MCCM | 151 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | COL 3 | authKW | 1287826 | 7% | 58% | 11 |
| 2 | CHEMICALLY MODIFIED TETRACYCLINES | authKW | 906241 | 7% | 41% | 11 |
| 3 | MANCHESTER CELLULAR METAB MCCM | address | 606666 | 2% | 100% | 3 |
| 4 | 4 DEDIMETHYLAMINO SANCYCLINE | authKW | 202222 | 1% | 100% | 1 |
| 5 | 6 DEOXY 6 DEMETHYL 4 DEDIMETHYLAMINOTETRACYCLINE | authKW | 202222 | 1% | 100% | 1 |
| 6 | BIOMED BRC | address | 202222 | 1% | 100% | 1 |
| 7 | CALCIUM CHELATION MMP INHIBITION | authKW | 202222 | 1% | 100% | 1 |
| 8 | CLIN NOVUM MED | address | 202222 | 1% | 100% | 1 |
| 9 | COP 9 SIGNALOSOME | authKW | 202222 | 1% | 100% | 1 |
| 10 | DISSOLUTION RATE LIMITED ABSORPTION | authKW | 202222 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Oncology | 751 | 37% | 0% | 56 |
| 2 | Pharmacology & Pharmacy | 326 | 28% | 0% | 43 |
| 3 | Medicine, Research & Experimental | 100 | 11% | 0% | 16 |
| 4 | Cell Biology | 96 | 15% | 0% | 22 |
| 5 | Biochemistry & Molecular Biology | 67 | 21% | 0% | 32 |
| 6 | Biophysics | 67 | 9% | 0% | 13 |
| 7 | Chemistry, Medicinal | 18 | 4% | 0% | 6 |
| 8 | Multidisciplinary Sciences | 16 | 2% | 0% | 3 |
| 9 | Cell & Tissue Engineering | 6 | 1% | 0% | 1 |
| 10 | Hematology | 5 | 3% | 0% | 4 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | MANCHESTER CELLULAR METAB MCCM | 606666 | 2% | 100% | 3 |
| 2 | BIOMED BRC | 202222 | 1% | 100% | 1 |
| 3 | CLIN NOVUM MED | 202222 | 1% | 100% | 1 |
| 4 | ECM MED | 202222 | 1% | 100% | 1 |
| 5 | GROWTH SCI | 202222 | 1% | 100% | 1 |
| 6 | JINGZHOU HOSPTONGJI MED HUST | 202222 | 1% | 100% | 1 |
| 7 | KOCATEPE MED | 202222 | 1% | 100% | 1 |
| 8 | MED IVARTES MED | 202222 | 1% | 100% | 1 |
| 9 | SYLVESTER COMPREHEN CANC | 202222 | 1% | 100% | 1 |
| 10 | MCCM | 129995 | 2% | 21% | 3 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | ENDOCRINOLOGY AND METABOLISM | 2558 | 1% | 1% | 1 |
| 2 | ONCOTARGET | 1327 | 6% | 0% | 9 |
| 3 | JOURNAL OF LABORATORY AND CLINICAL MEDICINE | 1255 | 3% | 0% | 5 |
| 4 | TOPICS IN COMPANION ANIMAL MEDICINE | 905 | 1% | 0% | 1 |
| 5 | CURRENT MEDICINAL CHEMISTRY | 729 | 3% | 0% | 4 |
| 6 | PROCEEDINGS OF THE KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN SERIES C-BIOLOGICAL AND MEDICAL SCIENCES | 674 | 1% | 0% | 1 |
| 7 | ISRAEL JOURNAL OF VETERINARY MEDICINE | 668 | 1% | 0% | 1 |
| 8 | ENDOCRINOLOGIA EXPERIMENTALIS | 615 | 1% | 0% | 1 |
| 9 | CANCER LETTERS | 595 | 4% | 0% | 6 |
| 10 | INVASION & METASTASIS | 460 | 1% | 0% | 1 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | SAGAR, J , SALES, K , DIJK, S , TAANMAN, J , SEIFALIAN, A , WINSLET, M , (2009) DOES DOXYCYCLINE WORK IN SYNERGY WITH CISPLATIN AND OXALIPLATIN IN COLORECTAL CANCER?.WORLD JOURNAL OF SURGICAL ONCOLOGY. VOL. 7. ISSUE . P. - | 13 | 81% | 5 |
| 2 | SAGAR, J , SALES, K , DIJK, S , TAANMAN, J , SEIFALIAN, A , WINSLET, M , (2009) DOES DOXYCYCLINE WORK IN SYNERGY WITH CISPLATIN AND OXALIPLATIN IN COLORECTAL CANCER?.WORLD JOURNAL OF SURGICAL ONCOLOGY. VOL. 7. ISSUE . P. - | 13 | 81% | 5 |
| 3 | SAGAR, J , SALES, K , SEIFALIAN, A , WINSLET, M , (2010) DOXYCYCLINE IN MITOCHONDRIAL MEDIATED PATHWAY OF APOPTOSIS: A SYSTEMATIC REVIEW.ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY. VOL. 10. ISSUE 7. P. 556 -563 | 15 | 56% | 11 |
| 4 | SAGAR, J , SALES, K , TAANMAN, JW , DIJK, S , WINSLET, M , (2010) LOWERING THE APOPTOTIC THRESHOLD IN COLORECTAL CANCER CELLS BY TARGETING MITOCHONDRIA.CANCER CELL INTERNATIONAL. VOL. 10. ISSUE . P. - | 12 | 71% | 5 |
| 5 | VIERA, MH , PEREZ, OA , BERMAN, B , SERRADELL, N , ROSA, E , BOLOS, J , (2007) INCYCLINIDE - DUAL MMP-2/MMP-9 INHIBITOR TREATMENT OF ACNE - TREATMENT OF ROSACEA.DRUGS OF THE FUTURE. VOL. 32. ISSUE 3. P. 209-214 | 17 | 49% | 3 |
| 6 | SUN, T , ZHAO, N , NI, CS , ZHAO, XL , ZHANG, WZ , SU, X , ZHANG, DF , GU, Q , SUN, BC , (2009) DOXYCYCLINE INHIBITS THE ADHESION AND MIGRATION OF MELANOMA CELLS BY INHIBITING THE EXPRESSION AND PHOSPHORYLATION OF FOCAL ADHESION KINASE (FAK).CANCER LETTERS. VOL. 285. ISSUE 2. P. 141-150 | 15 | 45% | 12 |
| 7 | ONODA, T , ONO, T , DHAR, DK , YAMANOI, A , NAGASUE, N , (2006) TETRACYCLINE ANALOGUES (DOXYCYCLINE AND COL-3) INDUCE CASPASE-DEPENDENT AND -INDEPENDENT APOPTOSIS IN HUMAN COLON CANCER CELLS.INTERNATIONAL JOURNAL OF CANCER. VOL. 118. ISSUE 5. P. 1309-1315 | 16 | 41% | 49 |
| 8 | SONG, H , FARES, M , MAGUIRE, KR , SIDEN, A , POTACOVA, Z , (2014) CYTOTOXIC EFFECTS OF TETRACYCLINE ANALOGUES (DOXYCYCLINE, MINOCYCLINE AND COL-3) IN ACUTE MYELOID LEUKEMIA HL-60 CELLS.PLOS ONE. VOL. 9. ISSUE 12. P. - | 14 | 36% | 5 |
| 9 | TOBERER, F , HARTSCHUH, W , HADASCHIK, E , (2013) PRIMARY CUTANEOUS CD4(+) SMALL- TO MEDIUM-SIZED PLEOMORPHIC T-CELL LYMPHOMA TEMPORARY REMISSION BY ORAL DOXYCYCLINE.JAMA DERMATOLOGY. VOL. 149. ISSUE 8. P. 956-959 | 8 | 62% | 3 |
| 10 | ACHARYA, MR , VENITZ, E , FIGG, WD , SPARREBOOM, A , (2004) CHEMICALLY MODIFIED TETRACYCLINES AS INHIBITORS OF MATRIX METALLOPROTEINASES.DRUG RESISTANCE UPDATES. VOL. 7. ISSUE 3. P. 195 -208 | 23 | 24% | 82 |
Classes with closest relation at Level 1 |